Ángel Romo-Navarro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ángel Romo-Navarro has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Esperanza Carabias López
Department of Pathology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain
2 shared publications- Juan Ruiz Martín
Department of Pathology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain
2 shared publications Ana Rosa Parra Tercero
Department of Pathology. Hospital Universitario de Toledo, Toledo, Spain
1 shared publicationAna Rosa Parra-Tercero
Department of Pathology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain
1 shared publication- Begoña Otero Alen
Pathology Department, Biomedical Research Institute A Coruña (INIBIC) University Hospital Complex A Coruña A Coruña Spain
1 shared publication Carlos Quimbayo-Arcila
Department of Pathology, Complejo Hospitalario Universitario de Toledo, Toledo, Spain
1 shared publication
Latest Publications
- 15 October 2026
- Published by Elsevier in Gastroenterología y Hepatología
- p. 502872
Unexpected yellow nodules in the esophagus: When common histology becomes uncommon
- 15 October 2026
- Published by Elsevier in Gastroenterología y Hepatología
- p. 502872
Unexpected yellow nodules in the esophagus: When common histology becomes uncommon
- Open Access
- 15 October 2026
- Published by Springer Nature in Diagnostic Pathology
Prognostic value of Ki-67 in non-metastatic colorectal adenocarcinoma: a retrospective study
Background: Ki-67 is a cellular proliferation marker with an established prognostic role in several types of human tumors, whereas its prognostic significance in colorectal cancer remains uncertain. We assessed its prognostic value in an independent retrospective cohort of patients with non-metastatic colorectal adenocarcinoma. Methods: Overall survival (OS) and disease-free survival (DFS) were analyzed using Kaplan–Meier survival analysis and Cox proportional hazards regression, both in the overall cohort and stratified according to adjuvant therapy. Results: Among 207 cases, 132 (63.8%) and 75 (36.2%) showed high (≥ 50%) and low (< 50%) Ki-67, respectively. Kaplan–Meier analysis showed no significant differences in OS according to Ki-67 status ( p = 0.158), whereas DFS differed significantly ( p = 0.032). Fifteen-year DFS was 59% in the high Ki-67 group compared with 46% in the low Ki-67 group. In stratified multivariable Cox regression analysis, higher Ki-67 was significantly associated with a lower hazard of a DFS event among patients receiving adjuvant therapy (hazard ratio per 1-percentage-point increase = 0.954, 95% confidence interval: 0.925–0.984; p = 0.003). Conclusions: In patients with non-metastatic colorectal adenocarcinoma receiving conventional adjuvant therapy, low Ki-67 (< 50%) may identify a subgroup with significantly shorter DFS.
- 15 October 2026
- Published by Springer Nature in Diagnostic Pathology
Open AccessPrognostic value of Ki-67 in non-metastatic colorectal adenocarcinoma: a retrospective study
Background: Ki-67 is a cellular proliferation marker with an established prognostic role in several types of human tumors, whereas its prognostic significance in colorectal cancer remains uncertain. We assessed its prognostic value in an independent retrospective cohort of patients with non-metastatic colorectal adenocarcinoma. Methods: Overall survival (OS) and disease-free survival (DFS) were analyzed using Kaplan–Meier survival analysis and Cox proportional hazards regression, both in the overall cohort and stratified according to adjuvant therapy. Results: Among 207 cases, 132 (63.8%) and 75 (36.2%) showed high (≥ 50%) and low (< 50%) Ki-67, respectively. Kaplan–Meier analysis showed no significant differences in OS according to Ki-67 status ( p = 0.158), whereas DFS differed significantly ( p = 0.032). Fifteen-year DFS was 59% in the high Ki-67 group compared with 46% in the low Ki-67 group. In stratified multivariable Cox regression analysis, higher Ki-67 was significantly associated with a lower hazard of a DFS event among patients receiving adjuvant therapy (hazard ratio per 1-percentage-point increase = 0.954, 95% confidence interval: 0.925–0.984; p = 0.003). Conclusions: In patients with non-metastatic colorectal adenocarcinoma receiving conventional adjuvant therapy, low Ki-67 (< 50%) may identify a subgroup with significantly shorter DFS.
- 1 September 2026
- Published by Elsevier in Revista Española de Patología
- Vol. 59 (4)
Primary vulvar extramammary Paget disease associated with herpes simplex virus infection: A rare case report
- 1 September 2026
- Published by Elsevier in Revista Española de Patología
- Vol. 59 (4)
Primary vulvar extramammary Paget disease associated with herpes simplex virus infection: A rare case report
- Open Access
- 6 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11795
Disease-Free Survival of Patients with Stage II Stroma-Rich Colorectal Adenocarcinomas with Microsatellite Stability
Up to 25% of stage II colorectal adenocarcinomas recur within the first five years after diagnosis. The assessment of the stromal percentage, recently incorporated into the TNM classification system, may represent a particularly relevant predictive factor for recurrence in cases with microsatellite stability. We evaluated disease-free survival (DFS) in an independent retrospective cohort, measured the stromal percentage across the entire invasive front of the tumor, and assessed the interobserver agreement of this measurement method. Among 131 cases, 16 (12.2%) showed a high stromal percentage and 115 (87.8%) a low one. A high stromal percentage was associated with high-grade budding (p = 0.006). The 5-year DFS was 57% for high-stroma cases versus 76% for low-stroma cases (p < 0.001). Lymphatic invasion (HR: 16.513; p < 0.001) and a high stromal percentage (HR: 4.366; p = 0.006) had a statistically significant correlation with DFS. Interobserver agreement for global stromal assessment was very good (kappa index = 0.870; p < 0.001). In conclusion, the stromal percentage may be a predictive factor for recurrence, particularly relevant in stage II microsatellite-stable colorectal adenocarcinomas. Global stromal assessment appears to be a simple and easily reproducible method.
- 6 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11795
Open AccessDisease-Free Survival of Patients with Stage II Stroma-Rich Colorectal Adenocarcinomas with Microsatellite Stability
Up to 25% of stage II colorectal adenocarcinomas recur within the first five years after diagnosis. The assessment of the stromal percentage, recently incorporated into the TNM classification system, may represent a particularly relevant predictive factor for recurrence in cases with microsatellite stability. We evaluated disease-free survival (DFS) in an independent retrospective cohort, measured the stromal percentage across the entire invasive front of the tumor, and assessed the interobserver agreement of this measurement method. Among 131 cases, 16 (12.2%) showed a high stromal percentage and 115 (87.8%) a low one. A high stromal percentage was associated with high-grade budding (p = 0.006). The 5-year DFS was 57% for high-stroma cases versus 76% for low-stroma cases (p < 0.001). Lymphatic invasion (HR: 16.513; p < 0.001) and a high stromal percentage (HR: 4.366; p = 0.006) had a statistically significant correlation with DFS. Interobserver agreement for global stromal assessment was very good (kappa index = 0.870; p < 0.001). In conclusion, the stromal percentage may be a predictive factor for recurrence, particularly relevant in stage II microsatellite-stable colorectal adenocarcinomas. Global stromal assessment appears to be a simple and easily reproducible method.
- Open Access
Performance and Prognostic Relevance of Lymph Node Assessment by One-Step Nucleic Acid Amplification Assay in Rectal Cancer: A Multicenter Study
Background/Objectives: Lymph node metastases (LNM) undetected by standard hematoxylin and eosin (H&E) have been associated with unfavorable prognosis in colorectal cancer. The One-Step Nucleic Acid Amplification (OSNA) assay has demonstrated superior sensitivity in detecting LNM compared to H&E. We aimed to assess the performance of OSNA in detecting LNM, as well as its prognostic value in rectal cancer (RC) patients. Methods: Lymph nodes (LNs) of patients from 15 centers were analyzed by both H&E and OSNA. The total tumor load (TTL) was defined as the sum of cytokeratin 19 mRNA copies/µL in all LNs from a surgical specimen, using a threshold of 250 copies/μL for OSNA positivity. Cox proportional hazard regression was used to assess the effect of TTL ≥ 250 or 6000 copies/μL on cancer-specific survival (CSS) and recurrence-free survival (RFS), with Firth’s method applied to account for low event rate. Results: A total of 97 RC patients were included. Of these, 84 patients were eligible for survival analysis. The sensitivity and specificity of OSNA, compared to H&E, were 91.7% and 84.7%, respectively. TTL ≥ 6000 versus 6000 copies/μL, only TTL ≥ 6000 copies/μL was significantly associated with worse CSS and RFS. Conclusions: The OSNA assay is highly sensitive for detecting LNM in RC patients. A TTL of ≥6000 copies/μL could identify a subset of RC patients with worse CSS and RFS who might benefit from adjuvant treatment or intensive surveillance.
Open AccessPerformance and Prognostic Relevance of Lymph Node Assessment by One-Step Nucleic Acid Amplification Assay in Rectal Cancer: A Multicenter Study
Background/Objectives: Lymph node metastases (LNM) undetected by standard hematoxylin and eosin (H&E) have been associated with unfavorable prognosis in colorectal cancer. The One-Step Nucleic Acid Amplification (OSNA) assay has demonstrated superior sensitivity in detecting LNM compared to H&E. We aimed to assess the performance of OSNA in detecting LNM, as well as its prognostic value in rectal cancer (RC) patients. Methods: Lymph nodes (LNs) of patients from 15 centers were analyzed by both H&E and OSNA. The total tumor load (TTL) was defined as the sum of cytokeratin 19 mRNA copies/µL in all LNs from a surgical specimen, using a threshold of 250 copies/μL for OSNA positivity. Cox proportional hazard regression was used to assess the effect of TTL ≥ 250 or 6000 copies/μL on cancer-specific survival (CSS) and recurrence-free survival (RFS), with Firth’s method applied to account for low event rate. Results: A total of 97 RC patients were included. Of these, 84 patients were eligible for survival analysis. The sensitivity and specificity of OSNA, compared to H&E, were 91.7% and 84.7%, respectively. TTL ≥ 6000 versus 6000 copies/μL, only TTL ≥ 6000 copies/μL was significantly associated with worse CSS and RFS. Conclusions: The OSNA assay is highly sensitive for detecting LNM in RC patients. A TTL of ≥6000 copies/μL could identify a subset of RC patients with worse CSS and RFS who might benefit from adjuvant treatment or intensive surveillance.